Table 1.
Demographic and clinical characteristics of the study participants in this study.
| Healthy controls (n = 20) | ALS patients (n = 22) | P value | |
|---|---|---|---|
| Age (years) | 54.5 ± 5.5 | 57.2 ± 10.2 | 0.27 |
| Sex (males/females) | 12/8 | 15/7 | 0.58 |
| Site of onset (bulbar/cervical/thoracic/lumbosacral) | — | 4/11/1/6 | — |
| Diagnostic category (definite/probable/possible) | — | 5/6/11 | — |
| ALSFRS-R score | — | 39.7 ± 7.4 | — |
| Disease duration (months) | — | 13.5 ± 11.5 | — |
| Disease progression rate | — | 0.69 ± 0.45 | — |
ALS: amyotrophic lateral sclerosis; ALSFRS-R: revised ALS Functional Rating Scale. The rate of disease progression was calculated using the equation: (48-ALSFRS-R)/disease duration. “—” denotes no data available.